Lehigh Valley Health Network

LVHN Scholarly Works
Department of Medicine

Novel Immunotherapy Treatments: The Adverse
Effects of Nivolumab.
Angela Magdaleno DO
Lehigh Valley Health Network, angela.magdaleno@lvhn.org

Wael Hanna MD
Lehigh Valley Health Network, Wael_A.Hanna@lvhn.org

Follow this and additional works at: https://scholarlyworks.lvhn.org/medicine
Part of the Internal Medicine Commons, Medical Sciences Commons, and the Nephrology
Commons
Published In/Presented At
Magdaleno, A. Hanna, W. (2017, October). Novel Immunotherapy Treatments: The Adverse Effects of Nivolumab. Poster Presented at:
The American Conference of Physicians (ACP) Regional Conference, Harrisburg, PA.

This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an
authorized administrator. For more information, please contact LibraryServices@lvhn.org.

Novel Immunotherapy Treatments: The Adverse Effects of Nivolumab
Angela Magdaleno DO and Wael Hanna MD
1

2

Internal Medicine Resident, Nephrology Fellow, Lehigh Valley Health Network, Allentown, Pennsylvania

1

2

DISCUSSION

INTRODUCTION
Nivolumab is a checkpoint immunotherapy that has become a primary treatment modality for patients
with advanced melanoma and non-small cell lung carcinoma (NSCLC). New immunotherapy treatments
can result in unique adverse events due to increased inflammation in any organ in the body.

Image 1: T cells inactivated by cancer cells through PD-L1/PDL2 receptor

Image 2: Nivolumab utilized to maintain T cell activation
against cancer cells, and some healthy cells

Immune related inflammation and metastatic disease in the pancreas
in combination with nivolumab immunotherapy likely caused
pancreatic insufficiency resulting in new-onset diabetes. The cause of
this phenomenon is presumed to be due to inappropriate activation of
T-cells resulting in damage to normal tissues. Few case reports have
highlighted adverse effects of nivolumab causing immune-related
pancreatitis or rapid onset insulin-dependent diabetes. The case report
herein demonstrates both immune-related pancreatitis and newonset insulin-dependent diabetes developing after only one treatment
with nivolumab. All medical professionals should be able to recognize
immune-related adverse events due to immunotherapy medications to
appropriately diagnose patients.

CASE REPORT
A 64-year-old Vietnamese male with a history of stage IIIA NSCLC
was treated with Taxol, Carboplatin and radiation therapy with
good response. Two years later, computed tomography (CT)
scan demonstrated metastases to the liver and pancreas. The
patient began treatment with nivolumab. Two weeks after the
initial nivolumab treatment, the patient complained of significant
abdominal pain. Repeat CT imaging showed disease progression
in the liver and pancreas with mild inflammation of the pancreatic
tail. Hospital admission blood work showed lipase of 4479 U/L
and CRP of 179 mg/L, which is consistent with immune related
pancreatitis. He was treated with methylprednisolone 1.2mg/kg/
day with improvement in pain and lipase levels. Ten days after
starting steroid treatment, outpatient lab work revealed significant
lab derangements including blood glucose 649 mg/dL, sodium
126 mmol/L, elevated creatinine of 1.35 mg/dL and an anion gap
of 14. The patient had no known history of diabetes. The patient
did complain of polyuria and polydipsia for the previous 10 days.
Hemoglobin A1C resulted at 11%. Glutamic acid decarboxylase
antibody was negative, islet cell antibody was negative, zinc
transporter 8 antibody was negative, and C Peptide level was low
at 0.3 ng/mL. The patient was started on insulin as treatment for
his elevated blood sugars and low insulin levels.

Image 3: CT Abdomen/Pelvis. Pancreatic mass noted.

Image 5: Immune related adverse reactions caused by Nivolumab.
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Image 4: CT Abdomen/Pelvis. Pancreatic inflammation
noted.

